In vitro anticancer activity of encapsulated polymeric nanoparticles of cabazitaxel and ruthenium compound NAMI-A drugs in the treatment of esophogeal cancer
Source abstract
Abstract
The study utilized poly(D,L-lactide-co-glycolide)-block-polyethylene glycol (PEG) (PLGA-PEG) to encapsulate cabazitaxel (CTX) and (imidazoleH)[trans-RuCl4(DMSO-S)(Im)] (NAMI-A) into nanoparticles (CN-NPs). The nanoparticles displayed several advantageous characteristics, such as a spherical morphology, small size (84.25 ± 1.36 nm), remarkably excellent encapsulation efficiency, and drug loading. The NPs had a smooth surface morphology, appropriate negative charge (− 21.2 ± 2.1 mV), optimal stability, and gradual release. The CN-NPs are implicated in the proliferation of KYSE-270 cells. Significantly, both NAMI-A and CTX, in both their free and nanoparticulate states, exhibited lower toxicity toward HUVECs when compared to KYSE-270 cells. The morphological changes of both cells were examined by biochemical staining, and the apoptotic mode of cell death was confirmed. BAX, Caspase-3, -8, and -9 expression levels were examined in KYSE-270 cells subjected to the different NPs. The findings indicate that the simultaneous delivery of CTX and NAMI-A nanoparticles can potentially remove esophageal cancer efficiently.Graphical abstract
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Synthesis and Characterization of Heterocyclic Compounds
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. H. Zhu, X. Ma, T. Ye, H. Wang, Z. Wang, Q. Liu, K. Zhao, Esophageal cancer in China: practice and research in the new era. Int. J. Cancer 152, 1741–1751 (2023)10.1002/ijc.34301 ↗
2. C. Liu, Y. Ma, Q. Qin, P. Wang, Y. Luo, P. Xu, Y. Cui, Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040, Thorac. Cancer 14, 3–11 (2023)
3. Y.-M. Yang, P. Hong, W.W. Xu, Q.-Y. He, B. Li, Advances in targeted therapy for esophageal cancer. Signal Transduct. Target. Ther. 5, 229 (2020)10.1038/s41392-020-00323-3 ↗
4. S. He, J. Xu, X. Liu, Y. Zhen, Advances and challenges in the treatment of esophageal cancer. Acta Pharm. Sin. B. 11, 3379–3392 (2021)10.1016/j.apsb.2021.03.008 ↗
5. D.J. Uhlenhopp, E.O. Then, T. Sunkara, V. Gaduputi, Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin. J. Gastroenterol. 13, 1010–1021 (2020)10.1007/s12328-020-01237-x ↗
6. J. Li, J. Xu, Y. Zheng, Y. Gao, S. He, H. Li, K. Zou, N. Li, J. Tian, W. Chen, Esophageal cancer: epidemiology, risk factors and screening. Chinese J. Cancer Res. 33, 535 (2021)10.21147/j.issn.1000-9604.2021.05.01 ↗
7. J.E. Rogers, M. Sewastjanow-Silva, R.E. Waters, J.A. Ajani, Esophageal cancer: emerging therapeutics. Expert Opin. Ther. Targets 26, 107–117 (2022)10.1080/14728222.2022.2036718 ↗
8. Z. Yang, D. Chi, Q. Wang, X. Guo, Q. Lv, Y. Wang, Improved antitumor activity and tolerability of cabazitaxel derived remote-loading liposomes. Int. J. Pharm. 589, 119814 (2020)10.1016/j.ijpharm.2020.119814 ↗
9. M. Sousa-Pimenta, L.M. Estevinho, A. Szopa, M. Basit, K. Khan, M. Armaghan, M. Ibrayeva, E. Sönmez Gürer, D. Calina, C. Hano, Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel. Front. Pharmacol. 14, 1157306 (2023)10.3389/fphar.2023.1157306 ↗
10. B. Sun, H. Jing, M.T. Mabrouk, Y. Zhang, H. Jin, J.F. Lovell, A surfactant-stripped cabazitaxel micelle formulation optimized with accelerated storage stability. Pharm. Dev. Technol. 25, 1281–1288 (2020)10.1080/10837450.2020.1818780 ↗
11. Q. Shuai, G. Zhao, X. Lian, J. Wan, B. Cen, W. Zhang, J. Liu, W. Su, H. Wang, Self-assembling poly (ethylene glycol)-block-polylactide-cabazitaxel conjugate nanoparticles for anticancer therapy with high efficacy and low in vivo toxicity. Int. J. Pharm. 574, 118879 (2020)10.1016/j.ijpharm.2019.118879 ↗
12. T. Li, X. Chen, J. Wan, X. Hu, W. Chen, H. Wang, Akt inhibition improves the efficacy of cabazitaxel nanomedicine in preclinical taxane-resistant cancer models. Int. J. Pharm. 607, 121017 (2021)
13. B. Sun, Novel Cabazitaxel Drug Delivery Systems for Cancer Treatment, (2021).10.1002/wnan.1854 ↗
14. Y. Chen, Y. Pan, D. Hu, J. Peng, Y. Hao, M. Pan, L. Yuan, Y. Yu, Z. Qian, Recent progress in nanoformulations of cabazitaxel. Biomed. Mater. 16, 32002 (2021)10.1088/1748-605X/abe396 ↗
15. M. Pourmadadi, A. Ghaemi, M. Shaghaghi, A. Rahdar, S. Pandey, Cabazitaxel-nano delivery systems as a cutting-edge for cancer therapy. J. Drug Deliv. Sci. Technol. 82, 104338 (2023)
16. D. Huang, Z. Tang, X. Pu, T. Wang, F. Gao, C. Li, A novel cabazitaxel liposomes modified with ginsenoside Rk1 for cancer targeted therapy. Acupunct. Herb. Med. 4, 113–121 (2024)10.1097/HM9.0000000000000096 ↗
17. E. Parhizkar, S.M. Samani, A. Sakhteman, S. Daneshamouz, G. Parhizkar, F. Ahmadi, Synthesis, cytotoxicity assay, pharmacokinetics, biodistribution and modeling study of cabazitaxel-dextran nanoconjugates: targeted vs non targeted delivery. Coll. Surf. B Biointerfaces 209, 112187 (2022)10.1016/j.colsurfb.2021.112187 ↗
18. D. Pereira, N. Alves, Â. Sousa, J.F.A. Valente, Metal-based approaches to fight cervical cancer. Drug Discov. Today 29, 104073 (2024)10.1016/j.drudis.2024.104073 ↗
19. N. Nayeem, A. Yeasmin, S.N. Cobos, A. Younes, K. Hubbard, M. Contel, Investigation of the effects and mechanisms of anticancer action of a Ru (II)-Arene iminophosphorane compound in triple negative breast cancer cells. ChemMedChem 16, 3280–3292 (2021)10.1002/cmdc.202100325 ↗
20. P.K. Shah, P.K. Shukla, Effect of axial ligands on the mechanisms of action of Ru (III) complexes structurally similar to NAMI-A: a DFT study. Struct. Chem. 31, 679–689 (2020)10.1007/s11224-019-01439-1 ↗
21. S. Sadique, A.A. Baqer, A.W. Salman, M.A. Iqbal, M.M. Kadim, F. Jamil, A. Majeed, S. Manahil, A. Altaf, Ruthenium complexes for breast cancer therapy. Rev. Inorg. Chem. 44, 191–208 (2024)10.1515/revic-2023-0010 ↗
22. I.A. Shutkov, A.A. Antonets, V.Y. Tyurin, E.R. Milaeva, A.A. Nazarov, Ruthenium (III) complexes of NAMI-A type with ligands based on lonidamine and bexarotene as antiproliferative agents. Russ. J. Inorg. Chem. 66, 502–509 (2021)10.1134/S0036023621030177 ↗
23. M.G. Ferraro, M. Piccolo, G. Misso, F. Maione, D. Montesarchio, M. Caraglia, L. Paduano, R. Santamaria, C. Irace, Breast cancer chemotherapeutic options: a general overview on the preclinical validation of a multi-target Ruthenium (III) complex lodged in nucleolipid nanosystems. Cells 9, 1412 (2020)10.3390/cells9061412 ↗
24. S. Silvestri, I. Cirilli, F. Marcheggiani, P. Dludla, G. Lupidi, R. Pettinari, F. Marchetti, C. Di Nicola, G. Falcioni, C. Marchini, Evaluation of anticancer role of a novel ruthenium (II)-based compound compared with NAMI-A and cisplatin in impairing mitochondrial functionality and promoting oxidative stress in triple negative breast cancer models. Mitochondrion 56, 25–34 (2021)10.1016/j.mito.2020.11.004 ↗
25. H. Zhang, M. Cui, D. Tang, B. Wang, G. Liang, C. Xu, H. Xiao, Localization of cancer cells for subsequent robust photodynamic therapy by ROS Responsive polymeric nanoparticles with anti-metastasis complexes NAMI-A. Adv. Mater. 36, 2310298 (2024)10.1002/adma.202310298 ↗
26. S. Keshavarz Shahbaz, K. Koushki, O. Izadi, P.E. Penson, V.N. Sukhorukov, P. Kesharwani, A. Sahebkar, Advancements in curcumin-loaded PLGA nanoparticle delivery systems: progressive strategies in cancer therapy. J. Drug Target 32, 1–26 (2024)10.1080/1061186X.2024.2389892 ↗
27. A.M. Ramôa, F. Campos et al., Antimicrobial peptide-grafted PLGA-PEG nanoparticles to fight bacterial wound infections. Biomater. Sci. 11, 499–508 (2023)10.1039/D2BM01127A ↗
28. C.R. de Oliveira, D. Droppa-Almeida, F.F. Padilha, R.R. de Souza, R.L.C. de Albuquerque-Júnior, Polymeric nanoparticles for the treatment of prostate cancer-technological prospecting and critical analysis. Recent Pat. Nanotechnol. 17, 8–14 (2023)10.2174/1872210516666220131092642 ↗
29. M. Yao, M. Wu, M. Yuan, M. Wu, A. Shen, Y. Chen, D. Lian, X. Liu, J. Peng, Enhancing the therapeutic potential of isoliensinine for hypertension through PEG-PLGA nanoparticle delivery: a comprehensive in vivo and in vitro study. Biomed. Pharmacother. 174, 116541 (2024)
30. J. Wang, M. Xian, H. Cao, L. Wu, L. Zhou, Y. Ma, L. Fan, L. Lin, G. Li, Q. Huang, Prophylactic and therapeutic potential of magnolol-loaded PLGA-PEG nanoparticles in a chronic murine model of allergic asthma. Front. Bioeng. Biotechnol. 11, 1182080 (2023)10.3389/fbioe.2023.1182080 ↗
31. A. Verger, G. Dollo, N. Brandhonneur, S. Martinais, S. Cordier, K. Lang, M. Amela-Cortes, K. Kirakci, PEGylated poly (lactic-co-glycolic acid) nanoparticles doped with molybdenum-iodide nanoclusters as a promising photodynamic therapy agent against ovarian cancer. Mater. Adv. 4, 3207–3214 (2023)10.1039/D3MA00206C ↗
32. A.A. Rouhi, A. Valizadeh, N. Sedghizadeh, L. Beba, H. Dadashi, M. Kazempour, K. Adibkia, S. Vandghanooni, M. Eskandani, Targeted therapy of gastric cancer with gingerol-loaded hyaluronic acid/PEG-coated PLGA nanoparticles: development and physicochemical evaluation. J. Drug Deliv. Sci. Technol. 97, 105734 (2024)
33. M. Eskandani, A. Mohabbat, A. Karimiyan, H. Dadashi, K. Adibkia, Z. Sanaat, S. Vandghanooni, MUC1 aptamer-conjugated niclosamide-loaded PLGA-PEG nanoparticles attenuate HIF-1 stabilization upon hypoxia in MCF7 breast cancer cells. J. Drug Deliv. Sci. Technol. 92, 105278 (2024)
34. H. Tonbul, A. Şahin, S.C. Öztürk, G. Ultav, E. Tavukçuoğlu, S. Akbaş, Y. Aktaş, G. Esendağlı, Y. Çapan, An all-in-one nanoparticle for overcoming drug resistance: doxorubicin and elacridar co-loaded folate receptor targeted PLGA/MSN hybrid nanoparticles. J. Drug Target 32, 1–10 (2024)10.1080/1061186X.2024.2374034 ↗
35. N.H. Minh, C.V. Manh, A.L.T. Van, D.L.T. Thuy, Stability of soluble honokiol loaded PLGA-PEG nanoparticles under normal and accelerated-aging conditions. Adv. Nat. Sci. Nanosci. Nanotechnol. 14, 35004 (2023)10.1088/2043-6262/ace3b9 ↗
36. R. López-Rios de Castro, R.M. Ziolek, M.B. Ulmschneider, C.D. Lorenz, Therapeutic peptides are preferentially solubilized in specific microenvironments within PEG–PLGA polymer nanoparticles. Nano Lett. 24, 2011–2017 (2024)10.1021/acs.nanolett.3c04558 ↗
37. F. Sadeghzadeh, A.S. Ziaratnia, M. Homayouni Tabrizi, G.H. Torshizi, M. Alhajamee, D. Khademi, Nanofabrication of PLGA-PEG-chitosan-folic acid systems for delivery of colchicine to HT-29 cancer cells. J. Biomater. Sci. Polym. Ed 34, 1–17 (2023)10.1080/09205063.2022.2105103 ↗
38. H. Maleki, M.R. Hosseini Najafabadi, T.J. Webster, M.R. Hadjighassem, E. Sadroddiny, H. Ghanbari, M. Khosravani, M. Adabi, Effect of Paclitaxel/etoposide co-loaded polymeric nanoparticles on tumor size and survival rate in a rat model of glioblastoma. Int. J. Pharm. 604, 120722 (2021). https://doi.org/10.1016/j.ijpharm.2021.12072210.1016/j.ijpharm.2021.120722 ↗
39. S. Ganesan, V.J. Upadhye, D. Aulakh, S. Bishnoi, A. Chinnathambi, T.A. Alahmadi, S.M. Abudoleh, P. Arulselvan, I. Thangavelu, Dual drug co-encapsulation of bevacizumab and pemetrexed clocked polymeric nanoparticles improves antiproliferative activity and apoptosis induction in liver cancer cells. J. Appl. Polym. Sci. 141, e56262 (2024)10.1002/app.56262 ↗
40. A.S. Alshetaili, Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines, Saudi. J. Biol. Sci. 28, 5065–5073 (2021). https://doi.org/10.1016/j.sjbs.2021.05.02510.1016/j.sjbs.2021.05.025 ↗
41. S.S. Alhudaithi, M. Abul Kalam, L. Binobaid, R. Ali, M.M. Almutairi, W. Qamar, H. Bin Hithlayn, A. Almutairi, A.K. Alshememry, Sorafenib and Piperine co-loaded PLGA nanoparticles: development, characterization, and anti-cancer activity against hepatocellular carcinoma cell line. Saudi Pharm. J. 32, 102064 (2024). https://doi.org/10.1016/j.jsps.2024.10206410.1016/j.jsps.2024.102064 ↗
42. P.N.K. Sagoe, E.J.M. Velázquez, Y.M. Espiritusanto, A. Gilbert, T. Orado, Q. Wang, E. Jain, Fabrication of PEG-PLGA microparticles with tunable sizes for controlled drug release application. Molecules 28, 6679 (2023)10.3390/molecules28186679 ↗
43. A. Jha, M. Kumar, P. Goswami, K. Bharti, M. Manjit, A. Gupta, S. Moorkoth, B. Koch, B. Mishra, Cabazitaxel-loaded redox-responsive nanocarrier based on d-alpha-tocopheryl-chitosan and hyaluronic acid for improved antitumor efficacy in DMBA-induced breast cancer model. Mater. Adv. 5, 7789–7808 (2024)10.1039/D4MA00556B ↗
44. K. Giriraj, M.S. Mohamed Kasim, K. Balasubramaniam, S.K. Thangavel, J. Venkatesan, S. Suresh, P. Shanmugam, C. Karri, Various coordination modes of new coumarin Schiff bases toward Cobalt (III) ion: synthesis, spectral characterization, in vitro cytotoxic activity, and investigation of apoptosis. Appl. Organomet. Chem. 36, e6536 (2022). https://doi.org/10.1002/aoc.653610.1002/aoc.6536 ↗
45. S. Swaminathan, J. Haribabu, M.K. Mohamed Subarkhan, D. Gayathri, N. Balakrishnan, N. Bhuvanesh, C. Echeverria, R. Karvembu, Impact of aliphatic acyl and aromatic thioamide substituents on the anticancer activity of Ru(ii)-p-cymene complexes with acylthiourea ligands—in vitro and in vivo studies. Dalt. Trans. (2021). https://doi.org/10.1039/D1DT02611A10.1039/D1DT02611A ↗
46. G. Kalaiarasi, M. Mohamed Subarkhan, C.K. Fathima Safwana, S. Sruthi, T. Sathiya Kamatchi, B. Keerthana, S.L. Ashok Kumar, New organoruthenium(II) complexes containing N, X-donor (X = O, S) heterocyclic chelators: synthesis, spectral characterization, in vitro cytotoxicity and apoptosis investigation. Inorganica Chim. Acta. (2022). https://doi.org/10.1016/j.ica.2022.12086310.1016/j.ica.2022.120863 ↗
47. F. Khaki-Khatibi, M. Zeinali, B. Ramezani, M. Sabzichi, J. Mohammadian, H. Hamishehkar, Harnessing WYE-132 as an inhibitor of the mTOR signaling enriches the cytotoxicity effect of vinblastine in B16F10 melanoma cancer cells. Proc. Biochem. (2020). https://doi.org/10.1016/j.procbio.2020.08.02610.1016/j.procbio.2020.08.026 ↗
48. H. Wang, J. Mu, Y. Chen, Y. Liu, X. Li, H. Li, P. Cao, Hybrid ginseng-derived extracellular vesicles-like particles with autologous tumor cell membrane for personalized vaccination to inhibit tumor recurrence and metastasis. Adv. Sci. 11, 2308235 (2024)10.1002/advs.202308235 ↗
49. S. Montazersaheb, A. Eftekhari, A. Shafaroodi, S. Tavakoli, S. Jafari, A. Baran, M.F. Baran, S. Jafari, E. Ahmadian, Green-synthesized silver nanoparticles from peel extract of pumpkin as a potent radiosensitizer against triple-negative breast cancer (TNBC). Cancer Nanotechnol. 15, 47 (2024)10.1186/s12645-024-00285-z ↗
50. W. Xiong, Z. Cheng, H. Chen, H. Liang, M. Wang, Y. Chen, J. Ying, Y. Cai, J. Chai, K. Dou, Biomimetic tumor cell membrane-encapsulated nanoparticles combine NIR-II photothermal therapy and chemotherapy for enhanced immunotherapy in triple-negative breast cancer. Adv. Funct. Mater. 34, 2410841 (2024)10.1002/adfm.202410841 ↗
51. R. Tabassum, E. Dilshad, A comparative anticancer analysis of iron oxide nanoparticles of Hippophae rhamnoides and Cichorium intybus found in the Karakoram Range of Gilgit Baltistan against liver cancer targeting the RhoA gene, Drug Dev. Ind. Pharm. (2024) 1–10.10.1080/03639045.2024.2400209 ↗
52. M.K.M. Subarkhan, R. Ramesh, Ruthenium(II) arene complexes containing benzhydrazone ligands: synthesis, structure and antiproliferative activity. Inorg. Chem. Front. 3, 1245–1255 (2016). https://doi.org/10.1039/c6qi00197a10.1039/c6qi00197a ↗
53. X. Lin, Q. Wang, S. Du, Y. Guan, J. Qiu, X. Chen, D. Yuan, T. Chen, Nanoparticles for co-delivery of paclitaxel and curcumin to overcome chemoresistance against breast cancer. J. Drug Deliv. Sci. Technol. 79, 104050 (2023)
54. Q. Lu, W. Gao, Z. Chen, Z. Liu, J. Wang, L. Zeng, X. Hu, E. Zheng, Q. Zhang, H. Song, Co-delivery of Paclitaxel/Atovaquone/Quercetin to regulate energy metabolism to reverse multidrug resistance in ovarian cancer by PLGA-PEG nanoparticles. Int. J. Pharm. 655, 124028 (2024)
55. C. Cao, Y. Li, F. Shi, S. Jiang, Y. Li, L. Yang, X. Zhou, Y. Gao, F. Tang, H. Li, Nano co-delivery of doxorubicin and plumbagin achieves synergistic chemotherapy of hepatocellular carcinoma. Int. J. Pharm. 661, 124424 (2024)
56. S. Jo, S. Roh, J. Shim, J.W. Yu, Y. Jung, W.Y. Jang, B. Seo, Y.-Y. Won, J. Yoo, Modulating the thermoresponsive characteristics of PLGA–PEG-PLGA hydrogels via manipulation of PLGA monomer sequences. Biomacromol 25, 5374–5386 (2024)10.1021/acs.biomac.4c00817 ↗
57. L. Lu, L. Jie, Y. Zhou, J. Zhang, T. Feng, Y. Zhu, T. Chen, X. Zhu, J. Ji, Z. Wang, Preparation and characterization of PLGA-based magnetic polymer nanoparticles for targeting pancreatic adenocarcinoma. Curr. Pharm. Des. 29, 686–696 (2023)10.2174/1381612829666230324091555 ↗
58. S. Kadyr, A. Zhuraliyeva, A. Yermekova, A. Makhambetova, D.B. Kaldybekov, E.A. Mun, D. Bulanin, S.N. Askarova, B.A. Umbayev, PLGA-PEG nanoparticles loaded with Cdc42 inhibitor for colorectal cancer targeted therapy. Pharmaceutics 16, 1301 (2024)10.3390/pharmaceutics16101301 ↗
59. S. Kasibhatla, G.P. Amarante-Mendes, D. Finucane, T. Brunner, E. Bossy-Wetzel, D.R. Green, Acridine orange/ethidium bromide (AO/EB) staining to detect apoptosis. CSH Protoc. 2006, 799–803 (2006). https://doi.org/10.1101/pdb.prot449310.1101/pdb.prot4493 ↗
60. Y. Hu, D. Yu, X. Zhang, 9-amino acid cyclic peptide-decorated sorafenib polymeric nanoparticles for the efficient in vitro nursing care analysis of hepatocellular carcinoma. Proc. Biochem. (2021). https://doi.org/10.1016/j.procbio.2020.09.02110.1016/j.procbio.2020.09.021 ↗